Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-02Estimated
Enrollment · participants180Estimated
Source updated2026-11-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.